INTRODUCTION
Prostate adenocarcinoma (PCa) remains as one of the leading causes of cancer-related deaths for men in the western world. The National Cancer Institute estimates that 1 in 6 men in the United States will develop PCa in their lifetime, with an expected 1 in 36 men succumbing to the disease. Whereas organ-confined disease is often highly responsive to therapy, development of metastatic PCa reduces 5-year survival rates to only 28%. Several molecular mechanisms that govern the progression of PCa have been identified. Some of these include the loss of transcription factor NKX3.1 (1, 2) ; the increased expression of the gene encoding the oncogenic transcription factor MYC (3, 4) ; the presence of oncogenic gene fusions, including TMPRSS2-ERG translocations (5, 6) ; the loss of the phosphatase and tumor suppressor PTEN (7, 8) ; and enhanced mitogenactivated protein kinase (MAPK) signaling (9, 10) . Although progress has been made clinically for patients with primary tumors, few therapeutic options are available for patients with metastatic disease. Thereby, uncovering more of the factors governing the development of invasive and ultimately metastatic PCa will present new opportunities for therapeutic intervention.
Extracellular signal-regulated kinase 5 (ERK5), also known as big mitogenactivated protein kinase-1 (BMK1), is the most recently discovered member of the MAPK family [reviewed in (11) ]. ERK5 serves as an output for oncogenic receptor tyrosine kinase activity (12) and promotes osteosarcoma cancer cell invasion by inducing the expression of the genes encoding the transcription factor Slug and matrix metalloproteinase 9 (MMP9) (13) . ERK5 promotes an inflammatory tumor microenvironment by inducing mRNA multiple inflammatory cytokines such as interleukin-1a (IL-1a), IL-1b, and IL-8; inhibiting ERK5 prevents the secretion of IL-1b (14) . Increased ERK5 activity is associated with PCa progression in clinical specimens (15) and is shown to induce invasion by cultured PCa tumor cells through integrin-focal adhesion kinase signaling using electrode-based cell micromotion assays (16) and to promote metastasis in orthotopic models of PCa through the induction of multiple MMPs (17) .
Forkhead box F1 (FOXF1) is a member of the winged helix family of transcription factors with a known role in embryonic development (18, 19) . Postnatal expression of FOXF1 is confined to mesenchyme-derived cells, such as endothelium, fibroblasts, and smooth muscle cells, but not normal epithelial cells (20) . Although FOXF1 is implicated in epithelial carcinogenesis, its functional role is controversial. In breast cancer cell lines, FOXF1 has been shown to function as a tumor suppressor and is inactivated through hypermethylation of its promoter (21) . Hypermethylation of FOXF1 promoter was shown in a subpopulation of invasive ductal carcinomas (21) . In colon and breast cancer cell lines, FOXF1 protects cells from DNA re-replication (22) . Genomic analysis has shown that some human PCa cells have a loss of the 16q24 chromosome region, which contains several genes including FOXF1 (23) . On the basis of these tumor suppressor properties of FOXF1 in breast and colon cancers, it was proposed that FOXF1 is most probably a tumor suppressor in PCa cells that contain genomic deletions of 16q24, but this hypothesis had never been confirmed experimentally. In contrast, high amounts of FOXF1 are found in 78% of Hedgehog (HH)-positive non-small cell lung cancers, and this high abundance is positively correlated with metastasis (24) . Increased expression of FOXF1 is also found in basal cell carcinoma, medulloblastoma, and rhabdomyosarcomas (25, 26) . In addition, FOXF1 promotes a stem-like state in lung cancer cells (27) and activates epithelial-to-mesenchymal transition (EMT) in breast cancer cells (28) , raising the possibility that FOXF1 can function as an oncogene. These conflicting findings in different cancer types suggest that the role of FOXF1 in carcinogenesis is complex and depends on tissue specificity.
Here, we investigated the role of FOXF1 in prostate cancer using two orthotopic mouse models of PCa and found that FOXF1 drives PCa tumor cell proliferation and invasion through transactivation of the ERK5 pathway. New-generation ERK5 inhibitors are currently in development (29) ; our findings suggest that ERK5 inhibitors may be therapeutic in patients with FOXF1-positive PCa.
RESULTS

FOXF1 is not detected in normal prostate epithelium, but its abundance is increased in a subset of cells in prostate tumors
Immunohistochemistry demonstrated that FOXF1 protein was present in the stromal cells of the normal mouse prostate but was undetectable in the prostate epithelium (Fig. 1A) . However, during spontaneous prostate cancer development in SV-40 (simian virus 40) large and small T antigendriven TRAMP (transgenic adenocarcinoma of mouse prostate) transgenic mice (30) and in Myc oncogene-driven ARR2PB-c-Myc/Hi-Myc-CaP transgenic mice (31), FOXF1 protein was detected in a subset of epithelialderived tumor cells. Likewise, FOXF1 was detected in a subset of cells in human PCa (Fig. 1A) .
Overexpression of FOXF1 in PCa tumor cells increases the growth of orthotopic xenografts in mice
To examine the role for FOXF1 in PCa, we used lentiviral vectors to overexpress murine Foxf1 and express the luciferase reporter in Myc-CaP murine PCa cells that have extremely low amounts of Foxf1 on the mRNA level that is undetectable on the endogenous protein level (Fig. 1B) . The tumor cells were grafted orthotopically into the anterior prostate lobes of syngeneic male mice (32) . Luciferase-transfected Myc-CaP cells containing the empty vector instead of the FOXF1 vector were used as controls. Overexpression of FOXF1 in Myc-CaP cells increased the mass of primary tumors (Fig. 1C , upper panel), increased luciferase intensity in the lower abdomen (Fig. 1C , bottom panel), and induced metastatic dissemination of Myc-CaP cells into the peritoneal cavity (Fig. 1D) . About 90% of mice with FOXF1-positive tumor engraftments developed metastasis compared to only 10% of control mice (Fig. 1D) . To ensure that the role of FoxF1 is not limited to the Myc-CaP model of PCa, we examined the effects of FoxF1 in TRAMP orthotopic grafts by transducing TRAMP cells with Foxf1-expressing lentivirus. Similar to the Myc-CaP tumor model, we observed larger tumor sizes in the TRAMP FoxF1-OE orthotopic engraftments (Fig. 1E ). More than 75% of mice with TRAMP FoxF1-OE tumors had peritoneal metastasis, whereas no metastases were found in the control mice (Fig. 1F ). These results demonstrate that FOXF1 promotes PCa growth and metastasis in two orthotopic mouse models of prostate cancer.
FOXF1 promotes tumor cell proliferation in two mouse models of prostate cancer
Increased tumor weights in FOXF1-overexpressing (herein called "FoxF1-OE") Myc-CaP and TRAMP tumors were associated with the increased expression of proliferation-specific mRNAs, as shown by quantitative realtime reverse transcription polymerase chain reaction (qRT-PCR), including mRNAs encoding cyclin B1, cyclin D1, CDC25b, Aurora kinase B, FoxM1, and cyclin E1 (Fig. 2, A and B ). Because these genes induce cellular proliferation in various tumor models (30, 33) , immunohistochemistry was used to visualize cells undergoing cell cycle. The number of Ki-67-and phosphorylated histone H3-positive tumor cells was greater in FoxF1-OE Myc-CaP and TRAMP tumors than in controls (Fig. 2C) . In vitro analysis of FoxF1-OE tumor cells confirmed the in vivo findings, showing significantly higher proliferation of FoxF1-OE Myc-CaP cells compared to control tumor cells containing empty vector ( fig. S1, A to D) . Staining for cleaved caspase-3, a marker of apoptosis (33) , showed no significant difference in the number of apoptotic cells between control and FoxF1-OE Myc-CaP or TRAMP tumors (Fig. 2C) . Together, these data suggest that FoxF1 induces prostate tumor growth by increasing the proliferation of tumor cells.
FOXF1 induces prostate cancer cell invasion and metastasis
As described above, one of the more prominent effects of FOXF1 was the induction of local metastasis to the seminal vesicles and throughout the peritoneal cavity. Histology [hematoxylin and eosin (H&E)] staining demonstrated the invasive phenotype in the FoxF1-OE Myc-CaP tumors (Fig.  3A) , as well as a significantly higher number of peritoneal metastases detected per animal (Fig. 3B ). The expression of mRNAs encoding known mediators of prostate cancer invasion and progression (34) (35) (36) (37) , including the matrix metalloproteinases MMP2, MMP9, MMP10, and MMP13, the transcriptional activator ETS translocation variant 1, and S100 calciumbinding protein A8, was significantly increased in Myc-CaP tumor cells expressing FOXF1 (Fig. 3C ). There was no significant change in mRNA encoding stathmin 1, previously shown to be a prometastatic mechanism in PCa (Fig. 3C ). Similar to FoxF1-OE Myc-CaP tumors, the TRAMP FoxF1-OE xenografts had high frequency of local metastases per animal (Fig. 3D ) and exhibited a similar mRNA signature for genes involved in the tumor invasion and metastasis (Fig. 3E) . Analysis of FoxF1-OE tumor cells in culture assays confirmed the in vivo findings, showing significantly higher invasion by FoxF1-OE Myc-CaP and FoxF1-OE TRAMP cells than control tumor cells expressing an empty vector ( fig. S1 , E to H). Together, these results demonstrate that PCa tumors expressing FOXF1 are more aggressive and have a greater capacity to invade surrounding tissues and metastasize to the peritoneal cavity.
FOXF1 increases the expression of EMT-associated genes in PCa grafts
Considering the evidence that FoxF1-OE tumors were more aggressive, we next examined the expression of known markers of EMT, which is often associated with PCa aggressiveness (38, 39) . Within FoxF1-OE Myc-CaP orthotopic tumors, there was an overall decrease in the abundance of mRNA encoding the epithelial marker E-cadherin and a gain in that encoding mesenchymal marker N-cadherin ( fig. S2A ). The abundance of mRNA encoding the EMT-associated transcription factor SNAIL2 was increased in FoxF1-OE Myc-CaP tumors compared to control tumors ( fig. S2A ). TRAMP FoxF1-OE prostate tumors showed a similar pattern with the loss of epithelial E-cadherin and gain of mesenchymal markers N-cadherin and vimentin ( fig. S2B) . 
FOXF1 induces ERK5-MAPK signaling
To determine molecular mechanisms underlying FOXF1-induced prostate carcinogenesis, we performed RNA sequencing analysis on RNA isolated from TRAMP control and TRAMP FoxF1-OE prostate tumors. Outputs were analyzed and categorized on the basis of functional annotation using ToppGene Suite software (40) . This approach revealed a significant up-regulation of several components of the ERK5-MAPK signaling pathway (Fig. 4 , A to C). These include the expression of Map3k2 and Wnk1, which encode mitogen-activated protein kinase kinase kinase 2 (MAP3K2, also known as MEKK2) and an upstream kinase WNK lysine-deficient protein kinase 1 (WNK1), which are critical upstream activators of ERK5 (41, 42) . Incidentally, Mmp9, a downstream transcriptional target of ERK5-MAPK signaling, was also induced in TRAMP (Fig. 5F ). Likewise, FOXF1 bound to the −4458/−4471 but not to the −2957/−2970 region of Wnk1 promoter (Fig.  5G) . Promoters of both Wnk1 and Map3k2 were cloned into luciferaseexpressing vectors and then cotransfected with a FOXF1 vector into human embryonic kidney (HEK) 293T cells. Relative luciferase signal indicated that FOXF1 increased the transcriptional activation of both Wnk1 and Map3k2 promoters, indicating that Wnk1 and Map3k2 genes are direct transcriptional targets of FoxF1 (Fig. 5, H and I) . Immunohistochemistry of Myc-CaP xenografts supported these data, in that MAP3K2 staining was substantially increased in FoxF1-OE tumors and correlated with increased staining for phosphorylated ERK5 (Fig. 5C) . Thus, FOXF1 transcriptionally activates Map3k2 and Wnk1 promoters and increases the phosphorylation of ERK5. Among human PCa cell lines, we identified 22RV1 and C4-2B cells as expressing high endogenous FOXF1 at both the mRNA and protein levels ( fig. S4 , A and E). In both human PCa cell lines, knocking down FOXF1 decreased tumor growth in orthotopic mouse models ( fig. S4B ), reduced the amount of MAP3K2 and WNK1 at both the mRNA and protein levels ( fig. S4 , C to E), and reduced the amount of ERK5 phosphorylation in tumor cells ( fig. S4E ). These results indicate that FOXF1 promotes growth and ERK5 signaling in 22RV1 and C4-2B human prostate tumors.
Inactivation of ERK5 or WNK1 and MAP3K2 reduces tumor growth and metastasis in FOXF1-positive prostate tumors
We next examined whether FoxF1 promotes prostate cancer growth and progression through the ERK5 signaling pathway. Considering that upstream activators of ERK5 pathway are transcriptional targets of FOXF1, targeting ERK5 itself represents a point where the two pathways converge, likely interfering with any potential compensatory mechanisms that might exist in the absence of either MAP3K2 or WNK1. Myc-CaP cells stably expressing FOXF1 were transduced with either lentivirus containing short hairpin RNA (shRNA) against Erk5 or control shRNA. Transduced Myc-CaP cells were then orthotopically transplanted into syngeneic mouse prostates. Depletion of ERK5 in FoxF1-OE tumors decreased tumor size and mass to those similar to control tumors (Fig. 6 , A to C) and prevented the development of peritoneal metastasis in these mice (Fig. 6 Decreased functional categories S5, E and F) . In addition, depletion of ERK5 decreased the abundance of cell proliferation markers in tumor cells to that observed in control tumors (Fig. 6E ) and decreased FOXF1-induced changes in the expression of genes associated with cell cycle (Fig. 6F) , EMT (Fig. 6G) , and extracellular matrix degradation (Fig. 6H) , supporting the notion that FOXF1 induces an invasive phenotype in PCa tumors through activation of ERK5. Thus, FOXF1 induces prostate tumor cell proliferation, invasion, and metastasis through ERK5. Consistent with above data suggesting a role for MAP3K2 and WNK1, depletion of both MAP3K2 and WNK1 from MycCaP tumor cells before orthotopic implantation into mice decreased tumor growth (Fig. 7A) , inhibited peritoneal metastasis (Fig. 7B) , and reduced the abundance of phosphorylated ERK5 (Fig. 7, C and D) . Furthermore, in human PCa tumors, the expression of FOXF1 was increased in a subset of the 58 patient samples (Fig. 7E  and fig. S6 ), and the expression of FOXF1 positively correlated with that of MAP3K2 and WNK1 (Fig. 7, F and G) . Together, our data indicate that FOXF1 stimulates prostate tumor growth and progression by inducing ERK5 signaling in tumor cells.
DISCUSSION
Previous studies have implicated FOXF1
as an oncogene (28), whereas others have reported it as a tumor suppressor (21, 43) . Although these studies appear to be conflicting, it is possible that FOXF1 has different functions depending on cell or tissue specificity. It is also possible that mutation status of tumor cells determines whether FOXF1 functions as an oncogene or tumor suppressor. Although the regulation of FOXF1 in tumor cells is largely unknown, tissue-specific contexts may account for activation of its expression in a subset of mouse and human PCa. To understand the context and effects of FOXF1 within the tumor cells in this study, we used orthotopic transplantation models for PCa. We found that neither c-Myc nor T antigen was sufficient to induce FOXF1 in prostate tumor cells because neither Myc-CaP nor TRAMP-C2RE3 cells expressed Foxf1 in cell culture conditions. By forcing ectopic expression of FOXF1 in these cell lines and subsequently transplanting these cells into the prostates of mice, we have uncovered a mechanism by which FoxF1 promotes PCa tumor growth and progression, that is, through activation of the ERK5-MAPK signaling pathway. FOXF1 appears to be important for multiple steps in PCa tumor progression, including tumor cell proliferation, invasion, and metastasis. Ectopic FOXF1 expression promoted tumor growth and metastatic dissemination to seminal vesicles and the peritoneal cavity in a manner dependent on the ERK5 pathway. Whereas aberrant ERK5 signaling has been shown to induce prostate tumor progression (14) (15) (16) (17) , factors that transcriptionally regulate this pathway are largely unknown. We found that FOXF1 transcriptionally activates Wnk1 and Map3k2, both of which are involved in the phosphorylation and activation of ERK5. Given that novel ERK5 inhibitors are in development (29) and that FOXF1 directly targets this pathway, it is possible that ERK5 may be an effective target in FOXF1-positive prostate cancers. It is also possible that the increased amount of FOXF1 in tumor cells within human PCa clinical specimens may be a predictive marker of ERK5 activation and consequently of tumors that are more likely to respond to ERK5 inhibitors.
Previous studies demonstrated that a rare subset of human PCa contains genomic deletion in 16q24 locus, which includes the FOXF1 gene (23) . These studies indicate that human 16q24 chromosome region likely contains a tumor suppressor. We found that suppression of WNK1 and MAP3K2 protein abundance inhibited the activation ERK5 and reduced the growth of FOXF1-positive tumors, suggesting that FOXF1 activates ERK5 signaling through WNK1 and MAP3K2. Given these results, it is unlikely that FOXF1 is the 16q24 tumor suppressor as was originally proposed. The 16q24 region contains several important genes, including two forkhead transcription factors, FOXC2 and FOXL1, and the noncoding RNA Fender, all of which have been implicated in regulating cell proliferation during embryonic development, vascular growth, and intestinal morphogenesis (44) (45) (46) . Therefore, it is possible that one of these genes may be the tumor suppressor that is lost in prostate tumors lacking the 16q24 gene locus.
MATERIALS AND METHODS
Mouse cell lines and orthotopic and transgenic tumor models
Foxf1-expressing plasmid pGIPZ-VSVG-GFP-Foxf1 and the control plasmid pGIPZ-VSVG-GFP were used to generate lentiviruses at Cincinnati Children's Hospital Viral Vector Core. Human prostate carcinoma cell lines and orthotopic models LNCaP, DU145, PC3, 22RV1 (purchased from the American Type Culture Collection), and C4-2B cell lines (a gift from S. Kasper, University of Cincinnati) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% antibiotics (Gibco). Plasmid constructs were obtained from the CCHMC shRNA Screening Core. Cells were transduced with lentivirus produced and purified by the CCHMC Viral Core Facilities. Cells were selected 2 days after transduction with puromycin. Knockdown was confirmed using qRT-PCR before tumor experiments. Subconfluent cell cultures were trypsinized, counted, and resuspended in type I collagen (BD Biosciences) to a density of 500,000 cells per injection. Suspended cells (10 ml) were injected directly into the anterior prostatic lobe of NOD-SCID-g (nonobese diabetic males of about 9 to 11 weeks old). Orthotopic tumors were harvested and microdissected at 4 weeks after implantation.
Immunohistochemistry
Immunostaining was performed as described (32) . The following antibodies were used for immunohistochemistry: FOXF1 (19), Ki-67 (Thermo Scientific, RM-9106-S0), phosphorylated histone H3 (Santa Cruz, 8656-R), cleaved caspase-3 (R&D Systems, AF835), ERK5 (Cell Signaling, 3552S), phosphorylated ERK5 (Cell Signaling, 3371S), and MAP3K2 (Abcam, ab33918).
Chromatin immunoprecipitation
Myc-CaP PCa cells stably expressing either FOXF1 or control vector were harvested, cross-linked using formaldehyde, sonicated to produce fragments of about 500 to 1000 base pairs (bp) in size, and immunoprecipitated using FOXF1 antibody (19) as previously described (48, 49) . Reverse cross-linked ChIP DNA samples were subjected to qPCR using oligonucleotides specific to promoter regions of mouse 
Quantitative RT-PCR
Total RNA was prepared from mouse prostates and analyzed by qRT-PCR using the StepOnePlus Real-Time PCR system (Applied Biosystems) as described (30) . RNA was amplified with TaqMan Gene Expression Master Mix (Applied Biosystems) combined with inventoried mouse gene expression assays. Inventoried TaqMan mouse gene assays are summarized in table S1.
Cell growth assay
Control or FoxF1-expressing TRAMP and Myc-CaP cells were plated in triplicate. Cells were counted at 1, 2, 3, and 4 days using a hemocytometer. The WST-1 assay (Roche) was used according to the manufacturer's instructions as described (50) . Experiments were performed in triplicates and presented as average numbers of cells ± SEM of three independent determinations.
Transwell invasion assay
Porous membranes (BD Biosciences) were coated with 100 ml of a 1:50 dilution of Matrigel (BD Biosciences) and allowed to dry overnight at room temperature. The following day, 100,000 control or Foxf1-expressing TRAMP or Myc-CaP cells were cultured on membranes in serum-free DMEM containing 0.1% bovine serum albumin. Cell invasion was induced by adding 5% serum to the lower chamber and was allowed to proceed at 37°C for 24 to 48 hours. Subsequently, Matrigel-invading cells were fixed with 95% ethanol. Cells remaining in the upper chamber were removed with a cotton swab, whereas those remaining in the lower chamber were stained with crystal violet. Invasion was quantified by counting the invading cells.
Scratch migration assay
Control and FoxF1-OE TRAMP or control and FoxF1-OE Myc-CaP cells were plated onto six-well plates and allowed to grow into confluent monolayers. Scrape "wounds" were generated using a 20-ml pipette tip, and the cell medium was replaced. Phase-contrast images of the cells were taken at 0, 4, 8, 12, and 24 hours after wounding, and the average scratch width was quantified using ImageJ (National Institutes of Health). The relative migration distance was calculated by dividing the width of the scratch at each time point by the width of the scratch at time 0. The relative distance was then converted to a percentage by multiplying by 100%. Experiments were done in triplicate.
Cloning of Map3k2 and Wnk1 promoters and the luciferase assay
Mouse genomic DNA was used to amplify the −6372/+1-bp region of the Wnk1 promoter [National Center for Biotechnology Information (NCBI) reference no. NC_000072.6] using the primers 5′-TTGTTTCC-TGGATGCCTTGTCCA-3′ and 5′-AAATGGCGCCCGATGTCT-GAAGC-3′. The same method was used to amplify the −5787-bp region to the +22-bp region of Map3K2 promoter (NCBI reference no. NC_000084.6) using the primers 5′-TCTGGCTCTAGGAAGGAG-GACTTG-3′ and 5′-TGTACACAGACCCGTGATGTCT-3′. PCR products were cloned into a pGL2 firefly luciferase reporter plasmid (Promega) and verified by DNA sequencing. HEK293T cells were transfected with CMV-Foxf1 or CMV-empty plasmids, as well as with luciferase reporter driven by the −5.7-kb Map3k2 promoter region (Map3k2-LUC) or by the −6.4-kb Wnk1 promoter region (Wnk1-LUC). CMV-Renilla was used as an internal control to normalize transfection efficiency. A dual luciferase assay (Promega) was performed 24 hours after transfection, as described previously (30) .
Human patient data set analysis
Human patient expression data were obtained through the Gene Expression Omnibus (GEO; GSE2109). Bioinformatics analysis was done using R with the Bioconductor suite. The "affy" package was used for normalization (51) . Expression values were normalized to endogenous housekeeping controls and compared to generate relative expression. GraphPad Prism was used on normalized expression values to perform Pearson's correlation and to evaluate statistical significance.
Statistical analysis
Microsoft Excel was used to calculate SD and statistically significant differences between samples using the Student's t test. P < 0.05 was considered statistically significant.
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